Further, Boukerroucha et al., 2015, that two breast cancer patients with hereditary BRCA1 gene mutations developed brain cancer later—hence monitoring of the DIG patient for breast and/or ovarian cancer development will be important. The gene discussed is BRCA1; the disease is ovarian cancer.